Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Baoxin Pill in HFpEF: Myocardial Energy Expenditure and LV Remodeling
ChiCTR2300076014Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Oct 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Shexiang Baoxin Pill arm with Placebo arm (2 arms). Primary endpoint: Myocardial energy expenditure. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2300076014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076014.